HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Reaction

Potassium Carbonate → 6-(2-(5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-ylamino)ethoxy)-3,4-dihydroquinolin-2(1H)-one

HRID 1023203
Print

Reaction equation

HRID 1023203 reaction equation
[F:1][C:2]([F:16])([F:15])[C:3]1[CH:8]=[CH:7][C:6]([C:9]2[O:13][C:12]([NH2:14])=[N:11][N:10]=2)=[CH:5][CH:4]=1.C(=O)([O-])[O-].[K+].[K+].CC1C=CC(S(O[CH2:34][CH2:35][O:36][C:37]2[CH:38]=[C:39]3[C:44](=[CH:45][CH:46]=2)[NH:43][C:42](=[O:47])[CH2:41][CH2:40]3)(=O)=O)=CC=1>CN(C=O)C.O>[F:16][C:2]([F:1])([F:15])[C:3]1[CH:4]=[CH:5][C:6]([C:9]2[O:13][C:12]([NH:14][CH2:34][CH2:35][O:36][C:37]3[CH:38]=[C:39]4[C:44](=[CH:45][CH:46]=3)[NH:43][C:42](=[O:47])[CH2:41][CH2:40]4)=[N:11][N:10]=2)=[CH:7][CH:8]=1
ParticipantsProcedureWorkupSources & evidenceReaction notes

Participants

6

Reactant 3

HCID 11430Potassium CarbonateHCID 52160855-[4-(Trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-amineHCID 866804362-(2-Oxo-1,2,3,4-tetrahydroquinolin-6-yloxy)ethyl 4-methylbenzenesulfonate

Product 1

HCID 715419406-(2-(5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-ylamino)ethoxy)-3,4-dihydroquinolin-2(1H)-oneYield 5.5%

Reagents, catalysts & solvents 2

HCID 962
Water
Solvent
HCID 6228DimethylformamideSolvent

Procedure

To a solution of 5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-amine (0.047 g, 0.207 mmol) in DMF (2 mL) was added potassium carbonate (0.052 g, 0.376 mmol) and 2-((2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)oxy)ethyl 4-methylbenzenesulfonate (0.068 g, 0.188 mmol) and the reaction stirred at room temperature for 15 h. The temperature was then increased to 60° C. for 15 h. After cooling to room temperature, the mixture was diluted with water (5 mL), extracted with EtOAC (20 mL), dried over sodium sulfate, and evaporated. The residue was purified by preparative HPLC on a X— Terra column (10×150 mm, 5 μm) with 0-100% AcCN in 10 mM aq. NH4OAc. Solvents were evaporated under vacuum to yield 6-(2-(5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-ylamino)ethoxy)-3,4-dihydroquinolin-2(1H)-one (4.3 mg, 5.5%). 1H NMR: 400 MHz, DMSO-d6: δ 2.53 (dd, J=7.60, 8.40 Hz, 2H), 2.91 (t, J=8.00 Hz, 2H), 3.76 (t, J=5.20 Hz, 2H), 4.20 (t, J=5.20 Hz, 2H), 6.80-6.84 (m, 3H), 7.83 (d, J=8.40 Hz, 2H), 8.07 (d, J=8.00 Hz, 2H). LCMS: RT 1.79 min. LCMS (ES-API), m/z 419.0 (M+H).

Workup

  1. temperatureThe temperature was then increased to 60° C. for 15 h
  2. temperatureAfter cooling to room temperature
  3. extractionextracted with EtOAC (20 mL)
  4. dry with materialdried over sodium sulfate
  5. customevaporated
  6. customThe residue was purified by preparative HPLC on a X— Terra column (10×150 mm, 5 μm) with 0-100% AcCN in 10 mM aq. NH4OAc
  7. customSolvents were evaporated under vacuum

Sources & evidence

ORD record
ord-a9bc3f2ce09c40c389184c84d667f163
Source dataset
uspto-grants-2014_05
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US08722670B2

Reaction notes

On this pageParticipantsProcedureWorkupSources & evidenceReaction notes